Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

NCT05702788 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor R\&D Strategy Adjustment

Conditions

COVID-19
Pneumonia

Interventions

DRUG: Jaktinib hydrochloride tablets
DRUG: Jaktinib hydrochloride tablets
OTHER: Placebo

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd